After the first application-specific, virtual US Food and Drug Administration advisory committee meeting on 14 July, it seemed fair to wonder if it might also be the last.
The Oncologic Drugs Advisory Committee’s review of GlaxoSmithKline plc's belantamab mafodotin for multiple myeloma was delayed at the outset by technical problems with GSK’s prerecorded presentation
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?